A competition aimed at tackling unequal access to healthcare in the NHS has been won by C2-Ai, a company that has developed an artificial intelligence-based risk assessmen
With waiting lists in the UK staying stubbornly above the 7 million mark, the Cheshire and Merseyside Integrated Care System (ICS) in the UK has turned to artificial intel
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh